<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT05041309</url>
  </required_header>
  <id_info>
    <org_study_id>KT-US-982-5968</org_study_id>
    <secondary_id>2020-005843-21</secondary_id>
    <nct_id>NCT05041309</nct_id>
  </id_info>
  <brief_title>Long-term Follow-up Study for Participants of Kite-Sponsored Interventional Studies Treated With Gene-Modified Cells</brief_title>
  <official_title>Long-term Follow-up Study for Participants of Kite-Sponsored Interventional Studies Treated With Gene-Modified Cells</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Kite, A Gilead Company</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Gilead Sciences</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
    <is_fda_regulated_drug>Yes</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      The primary objectives of this study are to:&#xD;
&#xD;
        -  Evaluate the incidence and severity of late-onset targeted adverse events (AEs)/serious&#xD;
           adverse events (SAEs) suspected to be possibly related to gene-modified cells, including&#xD;
           neurologic disorders, autoimmune disorders, hematologic disorders, serious infections,&#xD;
           and secondary malignancies&#xD;
&#xD;
        -  Evaluate mechanism of replication-competent retrovirus/replication-competent lentivirus&#xD;
           (RCR/RCL) and/or insertional mutagenesis for confirmed events related to the cell&#xD;
           therapy product&#xD;
&#xD;
        -  Evaluate the growth, development, and sexual maturity of pediatric and adolescent&#xD;
           subjects treated with gene-modified cells&#xD;
    </textblock>
  </brief_summary>
  <overall_status>Not yet recruiting</overall_status>
  <start_date type="Anticipated">November 2021</start_date>
  <completion_date type="Anticipated">November 2026</completion_date>
  <primary_completion_date type="Anticipated">November 2026</primary_completion_date>
  <phase>Phase 2</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Non-Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Percentage of Participants Experiencing Late-onset Targeted Adverse Events (AEs)</measure>
    <time_frame>Up to 15 years</time_frame>
    <description>Targeted AEs include late-onset targeted AEs suspected to be possibly related to gene-modified cells include neurologic disorders, autoimmune disorders, hematologic disorders, serious infections, and secondary malignancies.</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Percentage of Participants Experiencing Late-onset Targeted Serious Adverse Events (SAEs)</measure>
    <time_frame>Up to 15 years</time_frame>
    <description>Targeted SAEs include late-onset targeted SAEs suspected to be possibly related to gene-modified cells include neurologic disorders, autoimmune disorders, hematologic disorders, serious infections, and secondary malignancies.</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Vector Integration Site(s) for Replication-competent Retrovirus/Replication-competent Lentivirus (RCR/RCL) or Insertional Mutagenesis for Confirmed Events Related to the Cell Therapy Product</measure>
    <time_frame>Up to 15 years</time_frame>
  </primary_outcome>
  <primary_outcome>
    <measure>Height of Pediatric and Adolescent Participants</measure>
    <time_frame>Up to 15 years</time_frame>
  </primary_outcome>
  <primary_outcome>
    <measure>Weight of Pediatric and Adolescent Participants</measure>
    <time_frame>Up to 15 years</time_frame>
  </primary_outcome>
  <primary_outcome>
    <measure>Sexual Maturation of Pediatric and Adolescent Participants Assessed by Tanner Pubertal Stage Scale</measure>
    <time_frame>Up to 15 years</time_frame>
    <description>The Tanner Pubertal Stage Scale is a measure of pubertal development (sexual maturation) in children and adolescents with components described for each sex, rated separately on a scale of stage one to stage five, with 1 for preadolescent and 5 for mature/adult.</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Time to Subsequent Anticancer Therapies</measure>
    <time_frame>Up to 15 years</time_frame>
    <description>Time to subsequent anticancer therapies will be assessed only per regulatory request or sponsor needs.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Survival Status Assessment</measure>
    <time_frame>Up to 15 years</time_frame>
    <description>Survival status will be assessed as the length of time from the participant's first dose date of study drug to death during the study due to any cause or last date of being alive during the study. Survival status will be assessed only per regulatory request or sponsor needs.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Cause of Death</measure>
    <time_frame>Up to 15 years</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Peripheral B-cell and Lymphocytes Levels for Immune Reconstitution</measure>
    <time_frame>Up to 15 years</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Rate of Replication-competent Retrovirus/Replication-competent Lentivirus (RCR/RCL)</measure>
    <time_frame>Up to 15 years</time_frame>
  </secondary_outcome>
  <number_of_arms>6</number_of_arms>
  <enrollment type="Anticipated">700</enrollment>
  <condition>Solid and Hematological Malignancies</condition>
  <arm_group>
    <arm_group_label>Axicabtagene Ciloleucel</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>All participants who previously received axicabtagene ciloleucel in the parent study will be enrolled in this arm for long-term follow-up.&#xD;
In certain circumstances, participants may be eligible to receive a second course of axicabtagene ciloleucel treatment after enrolling in this long-term follow-up (LTFU) study at the same dose level that was administered in the completed parent study.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Brexucabtagene Autoleucel (KTE-X19)</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>All participants who previously received brexucabtagene autoleucel (KTE-X19) in the parent study will be enrolled in this arm for long-term follow-up.&#xD;
In certain circumstances, participants may be eligible to receive a second course of brexucabtagene autoleucel treatment after enrolling in this LTFU study at the same dose level that was administered in the completed parent study.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>KITE-585</arm_group_label>
    <arm_group_type>No Intervention</arm_group_type>
    <description>All participants who previously received KITE-585 in the parent study will be enrolled in this arm for long-term follow-up.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>KITE-718</arm_group_label>
    <arm_group_type>No Intervention</arm_group_type>
    <description>All participants who previously received KITE-718 in the parent study will be enrolled in this arm for long-term follow-up.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>KITE-439</arm_group_label>
    <arm_group_type>No Intervention</arm_group_type>
    <description>All participants who previously received KITE-439 in the parent study will be enrolled in this arm for long-term follow-up.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>KITE-222</arm_group_label>
    <arm_group_type>No Intervention</arm_group_type>
    <description>All participants who previously received KITE-222 in the parent study will be enrolled in this arm for long-term follow-up.</description>
  </arm_group>
  <intervention>
    <intervention_type>Biological</intervention_type>
    <intervention_name>Axicabtagene Ciloleucel</intervention_name>
    <description>A single infusion of chimeric antigen receptor (CAR)-transduced autologous T cells administered intravenously</description>
    <arm_group_label>Axicabtagene Ciloleucel</arm_group_label>
    <other_name>YescartaÂ®</other_name>
  </intervention>
  <intervention>
    <intervention_type>Biological</intervention_type>
    <intervention_name>Brexucabtagene Autoleucel (KTE-X19)</intervention_name>
    <description>A single infusion of chimeric antigen receptor (CAR)-transduced autologous T cells administered intravenously</description>
    <arm_group_label>Brexucabtagene Autoleucel (KTE-X19)</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          -  The individual must have received an infusion of gene-modified cells in a completed&#xD;
             Kite-sponsored parent study, has not withdrawn full consent, and has discontinued or&#xD;
             completed the post-treatment follow-up period in the parent study, as applicable&#xD;
&#xD;
          -  The individual must understand and voluntarily sign an Informed Consent Form (ICF) or&#xD;
             an Informed Assent Form prior to any study-related assessments or procedures being&#xD;
             conducted&#xD;
&#xD;
          -  In the investigator's judgment, the individual is willing and able to complete the&#xD;
             protocol-required follow-up schedule and comply with the study requirements for&#xD;
             participation&#xD;
&#xD;
        Exclusion Criteria: none&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>N/A</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Kite Study Director</last_name>
    <role>Study Director</role>
    <affiliation>Kite, A Gilead Company</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Medical Information</last_name>
    <phone>844-454-5483(1-844-454-KITE)</phone>
    <email>medinfo@kitepharma.com</email>
  </overall_contact>
  <link>
    <url>https://www.gileadclinicaltrials.com/study/?id=KT-US-982-5968</url>
    <description>Gilead Clinical Trials Website</description>
  </link>
  <verification_date>November 2021</verification_date>
  <study_first_submitted>August 27, 2021</study_first_submitted>
  <study_first_submitted_qc>September 7, 2021</study_first_submitted_qc>
  <study_first_posted type="Actual">September 13, 2021</study_first_posted>
  <last_update_submitted>November 4, 2021</last_update_submitted>
  <last_update_submitted_qc>November 4, 2021</last_update_submitted_qc>
  <last_update_posted type="Actual">November 11, 2021</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Hematologic Neoplasms</mesh_term>
  </condition_browse>
  <patient_data>
    <sharing_ipd>No</sharing_ipd>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

